Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

This study tests whether fenofibrate — a commonly used, generic cholesterol medication — can prevent primary sclerosing cholangitis (PSC) from returning after a liver transplant. PSC is a chronic bile duct disease with no established medical treatment, and recurrence after transplant occurs in up to 27% of patients and often leads to graft failure. Adults aged 18 to 75 who received a liver transplant for PSC between 1 and 7 years ago, show no signs of recurrence yet, and have at least one risk factor for recurrence (such as concurrent inflammatory bowel disease or prior acute rejection) may be eligible. Participation involves taking once-daily fenofibrate for 36 months, with regular blood tests, advanced liver imaging, and follow-up visits at Mayo Clinic Arizona every 4 months. This summary was generated with AI assistance to help patients understand the study in plain language.